Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

OREX 7.54 -0.26 (-3.33%)
price chart
Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
The launch of Orexigen Therapeutics' (NASDAQ: OREX ) obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million ...
UPDATE: Orexigen Therapeutics Shares Drop After Q4 Results  Benzinga
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and ...  PR Newswire (press release)
Orexigen Therapeutics, Inc. -- Stuck Between an Obese Rock and a Hard Place
Get 'em approved and keep selling 'em once they're on the market. Sure, there are details involved in accomplishing each, but from a high-level view, it's that simple.
Analyst: FDA Won't Pull Permit On Orexigen Therapeutics
Orexigen Therapeutics, Inc. (NASDAQ: OREX) sole product, the anti-obesity drug Contrave, almost certainly won't get pulled from the market, an analyst said Friday.
Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data  Wall Street Journal (blog)
Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. OREX Shares ...
On March 3, 2015, in connection with reporting to investors the status of certain patent applications Orexigen Therapeutics, Inc had sought for Contrave, Orexigen Therapeutics, Inc disclosed certain interim results of its ongoing LIGHT study. Shares of ...
Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ ...  GlobeNewswire (press release)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing therapies to treat obesity, surged higher by as much as 33% after the company reported its third-quarter earnings results and provided an ...
Orexigen Beats The Street On Milestone Payments (OREX)  Seeking Alpha (registration)
Orexigen Therapeutics Reports Results for the Third Quarter Ended September ...  PR Newswire (press release)
Related articles »  
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
In 2011, Orexigen was in a tight race with VIVUS (NASDAQ: VVUS ) and Arena Pharmaceuticals (NASDAQ: ARNA ) to gain FDA approval of the first new obesity drug.
Orexigen Wins U.S. FDA Approval for Weight-Loss Pill  Bloomberg
Takeda and Orexigen Announce FDA Approval of Contrave� (naltrexone HCI ...  MarketWatch
Related articles »  
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ, after reporting ...
Rocketed profits of Orexigen (NASDAQ:OREX) Therapeutics  WallStreet.org
Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy?  Zacks.com
Related articles »  
OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics, Inc ...
BENSALEM, Pa., Mar 25, 2015 (BUSINESS WIRE) -- Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of purchasers of the securities of Orexigen Therapeutics, Inc. (�Orexigen� or the �Company�) OREX, -0.37% ...
Orexigen Therapeutics, Inc. Rallies As Obesity Drug Mysimba Gets European ...  Bidness ETC
Buzz Stocks: BlackBerry Limited, The Dow Chemical Company, and Orexigen ...  Schaeffers Research (blog)
DEADLINE ALERT: Rigrodsky & Long, PA Reminds Shareholders Of Orexigen ...
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of Orexigen Therapeutics, Inc. (�Orexigen� or the �Company�) (NASDAQ GS: OREX) of an upcoming deadline involving a securities ...
Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Perilous Reversal" Stock
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
Orexigen Therapeutics (OREX) - Research Analysts' Weekly Ratings Changes  Mideast Time
Closing Bell Reports: 3M Company (MMM), Orexigen Therapeutics, Inc. (OREX ...  WallStreet Scope